New combo therapy for advanced lung cancer shows promise in early trial
NCT ID NCT03223155
First seen Mar 17, 2026 · Last updated May 08, 2026 · Updated 8 times
Summary
This early-stage trial is for people with stage IV non-small cell lung cancer. It tests whether giving immunotherapy drugs (nivolumab and ipilimumab) together with precise, high-dose radiation (SBRT) is safe. Participants are split into two groups: one gets radiation first, then immunotherapy; the other gets both at the same time. The goal is to find the best radiation dose for different tumor locations while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.